

Allergic Rhinitis

Allergic rhinitis is a global health problem affecting between 10% and 25% of the worldwide population. In the United States, the number of allergy sufferers is over 40 million people, 25-30 million of which suffer from allergic rhinitis. In the United Kingdom, the prevalence of allergic rhinitis is 16%, Denmark is 19%, and Germany between 13% and 17%. In different regions of the Russian Federation, the prevalence of allergic rhinitis ranges from 12.7% to 24%. The condition affects both children and adults, in both sexes. The highest prevalence of allergic rhinitis is observed in ecologically unfavorable regions. For instance, allergic rhinitis occupies more than 50% in the overall allergy prevalence among the population exposed to chemical and radiation factors.

Constant nasal congestion and other symptoms of rhinitis bring daily living burden by decreasing physical, occupational and social activity, or by causing sleep disturbance. Therefore, these significantly reduce patients' quality of life. Sufferers seek more effective treatments to ease their seasonal and/or year-round symptoms, including congestion, runny nose, and inflammation. In the continued effort to objectively research the viability of new allergy treatments, Pharm-Olam is proud to be working with a sponsor company on a Phase II Birch Allergy Immunotherapy study.

Therapeutic Area

Allergy

Patient Population

200+

Sites & Locations

25+ in Eastern and Western Europe

Services Provided

- Regulatory
- Project Management
- Pharmacovigilance
- Medical Monitoring
- Medical Writing
- Statistics
- Quality Assurance

Status

Recruitment Closed

Experience & Insights

Pharm-Olam's extensive experience in conducting Allergy trials across the globe dates back to when Dr. Zev Munk, an Immunologist, founded the company after years in private practice and allergy clinical research.

For over two decades, our Respiratory/Allergy experience has included studies involving: environmental exposure chambers, pollen counting centers, IDE testing and in-home dust mite testing. Experience, combined with our network of global investigators and allergy experts, ensures your Respiratory/Allergy trial is well-managed, delivered on time and on budget, no matter the complexity or challenge.

For more information about Pharm-Olam, please visit www.pharm-olam.com

About Pharm-Olam International

A multinational Contract Research Organization (CRO), Pharm-Olam offers comprehensive clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering high-quality data, achieving targeted enrollment and meeting projected timelines.

Pharm-Olam makes clinical research....**Easy As I, II, III, IV™**.

